Bicarbonate Deficit Calculator

The bicarbonate deficit estimates how much alkali is needed to raise serum bicarbonate to a chosen target, using the relation deficit in mEq equals body weight in kg times an apparent volume of distribution times the gap between target and measured bicarbonate. The volume of distribution term is the crux. Bicarbonate itself sits mainly in extracellular fluid, roughly 0.4 of body weight, but administered alkali is also consumed by intracellular protein and bone buffers, so the apparent volume expands as acidosis deepens: about 0.5 when bicarbonate is 10 to 15 mEq/L and 0.7 to 0.8 once it falls below 10. Normal serum bicarbonate is 22 to 26 mEq/L, and a level under 10 mEq/L with pH below 7.1 marks the range where most clinicians consider buffering at all. Only half the calculated deficit is given first, followed by a repeat arterial blood gas, because the formula is an approximation and endogenous bicarbonate regenerates as the underlying cause is treated. Sodium bicarbonate 8.4 percent supplies 1 mEq per mL in 50 mL ampules, so replacing a 245 mEq deficit also delivers 245 mEq of sodium in a solution of roughly 2000 mOsm/L. The predictable harms follow from that: hypernatremia, volume overload, overshoot alkalosis with transcellular potassium shift and a fall in ionized calcium, and generation of carbon dioxide that a patient with poor ventilatory reserve cannot exhale, which can worsen intracellular acidosis even as the serum number improves.

The chemistry underlying the calculation dates to 1908, when Lawrence Henderson expressed the equilibrium between carbon dioxide, carbonic acid and bicarbonate as an equation for blood hydrogen ion concentration, and to 1916, when Karl Albert Hasselbalch recast it in logarithmic form using Sorensen pH notation. Donald Van Slyke built the measurement side over the same period, developing volumetric and manometric apparatus that let laboratories quantify plasma carbon dioxide content and popularizing the concept of an alkali reserve. Bicarbonate as a therapy predates the theory, but rational dosing had to wait for these tools. Titration studies through the 1950s and 1960s, including acid-base work by William Schwartz and Arnold Relman in Boston and later analyses by Horacio Adrogue and Nicolaos Madias, measured how much administered alkali actually remained in the extracellular compartment and demonstrated that the apparent distribution space widens as acidemia worsens, producing the 0.4 to 0.8 range still quoted. Enthusiasm for the drug then narrowed sharply. Studies through the 1980s and 1990s found no benefit in lactic acidosis or diabetic ketoacidosis above a pH of 7.0, and the 2018 BICAR-ICU trial led by Samir Jaber found a survival benefit only in the subgroup with acute kidney injury. The deficit is now treated as an upper bound rather than a prescription.